rs2296147
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.040 |
GeneticVariation |
BEFREE |
XPG rs2296147 polymorphism could be predictive of unfavorable prognosis of CRC patients.
|
26887052 |
2016 |
rs2094258
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.050 |
GeneticVariation |
BEFREE |
Xeroderma pigmentosum group G rs2094258 polymorphism was associated with an increased risk of GC in a Chinese population.
|
29732643 |
2018 |
rs121434575
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs267607280
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs267607281
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs121434576
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.710 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs121434571
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.700 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs121434574
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.700 |
GeneticVariation |
UNIPROT |
A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: implications for a second XPG function.
|
9096355 |
1997 |
rs121434575
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs267607280
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs267607281
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.800 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs121434576
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.710 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs121434571
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.700 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs121434574
|
ERCC5;BIVM-ERCC5
|
Xeroderma pigmentosum, group G
|
|
0.700 |
GeneticVariation |
UNIPROT |
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy.
|
10447254 |
1999 |
rs17655
|
ERCC5;BIVM-ERCC5
|
Malignant neoplasm of colon and/or rectum
|
|
0.060 |
GeneticVariation |
BEFREE |
Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population.
|
25332048 |
2014 |
rs751402
|
ERCC5;BIVM-ERCC5
|
Malignant neoplasm of stomach
|
|
0.100 |
GeneticVariation |
BEFREE |
By unconditional logistic regression analysis, we</span> observed that the TT genotype in rs751402</span> was significantly associated with increased risk to gastric cancer as compared with the CC genotype, and the adjusted OR (95%CI) was 2.17 (1.15-4.09).
|
27706622 |
2016 |
rs751402
|
ERCC5;BIVM-ERCC5
|
Stomach Carcinoma
|
|
0.100 |
GeneticVariation |
BEFREE |
By unconditional logistic regression analysis, we</span> observed that the TT genotype in rs751402</span> was significantly associated with increased risk to gastric cancer as compared with the CC genotype, and the adjusted OR (95%CI) was 2.17 (1.15-4.09).
|
27706622 |
2016 |
rs2227869
|
ERCC5;BIVM-ERCC5
|
Thyroid Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Considering papillary TC, the rs2228001 (XPC) variant genotype was associated with increased risk (OR=2.33, 95% CI=1.05-5.16), while a protective effect was observed for rs2227869 (ERCC5) (OR=0.26, 95% CI=0.08‑0.90, for heterozygous; OR=0.25, 95% CI=0.07-0.86, for variant allele carriers).
|
23982724 |
2013 |
rs2227869
|
ERCC5;BIVM-ERCC5
|
Malignant neoplasm of thyroid
|
|
0.010 |
GeneticVariation |
BEFREE |
Considering papillary TC, the rs2228001 (XPC) variant genotype was associated with increased risk (OR=2.33, 95% CI=1.05-5.16), while a protective effect was observed for rs2227869 (ERCC5) (OR=0.26, 95% CI=0.08‑0.90, for heterozygous; OR=0.25, 95% CI=0.07-0.86, for variant allele carriers).
|
23982724 |
2013 |
rs2227869
|
ERCC5;BIVM-ERCC5
|
Thyroid carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
Considering papillary TC, the rs2228001 (XPC) variant genotype was associated with increased risk (OR=2.33, 95% CI=1.05-5.16), while a protective effect was observed for rs2227869 (ERCC5) (OR=0.26, 95% CI=0.08‑0.90, for heterozygous; OR=0.25, 95% CI=0.07-0.86, for variant allele carriers).
|
23982724 |
2013 |
rs17655
|
ERCC5;BIVM-ERCC5
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox proportional hazards analyses demonstrated that variant genotypes of XPG Asp1104His [hazard ratio (HR) = 1.692, 95% confidence interval (95%CI): 1.202-2.383, P = 0.003] as well as pathology grade (HR = 2.545, 95%CI: 2.139-3.030, P < 0.001), and lymph node metastases (HR = 1.851, 95%CI: 1.306-2.625, P < 0.001) were predictive of shorter PFS for the CRC patients with Oxaliplatin-based adjuvant chemotherapy.
|
22213216 |
2012 |
rs17655
|
ERCC5;BIVM-ERCC5
|
leiomyosarcoma
|
|
0.010 |
GeneticVariation |
BEFREE |
DNA from 93 patients with synovial sarcomas, myxoid liposarcomas, dermatofibrosarcomas protuberans (DFSP), malignant fibrous histiocytomas and leiomyosarcomas were genotyped for both XPD Lys751Gln and XPG Asp1104His polymorphisms.
|
16646069 |
2006 |
rs1047768
|
ERCC5;BIVM-ERCC5
|
Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
rs17655
|
ERCC5;BIVM-ERCC5
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation |
BEFREE |
ERCC1 rs11615 and ERCC5 rs17655 polymorphisms were associated with a moderately increased risk of this cancer in ever drinkers.
|
24563277 |
2014 |
rs17655
|
ERCC5;BIVM-ERCC5
|
Primary malignant neoplasm
|
|
0.050 |
GeneticVariation |
BEFREE |
ERCC1 rs11615 and ERCC5 rs17655 polymorphisms were associated with a moderately increased risk of this cancer in ever drinkers.
|
24563277 |
2014 |